Koers Isodiol International Inc. Canadian Securities Exchange
Aandelen
ISOL
CA46500L2003
Farmaceutische producten
Omzet 2018 | 19,14 mln. 26,34 mln. 17,72 mln. | Omzet 2019 | 22,25 mln. 30,62 mln. 20,6 mln. | Marktkapitalisatie | 49,96 mln. 68,76 mln. 46,26 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2018 | -36 mln. -49,55 mln. -33,33 mln. | Nettowinst (verlies) 2019 | -126 mln. -173 mln. -117 mln. | EV/omzet 2018 | 12,6 x |
Nettoliquiditeiten 2018 | 15,55 mln. 21,4 mln. 14,4 mln. | Nettoschuld 2019 | 5,22 mln. 7,19 mln. 4,84 mln. | EV/omzet 2019 | 2,48 x |
K/w-verhouding 2018 |
-4,94
x | K/w-verhouding 2019 |
-0,37
x | Werknemers | - |
Dividendrendement 2018 * |
-
| Dividendrendement 2019 |
-
| Vrij verhandelbaar | 100% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Marcos Agramont
CEO | Chief Executive Officer | - | 24-05-17 |
Director/Board Member | - | 30-08-18 | |
Kevin Swadish
PRN | Corporate Officer/Principal | - | 14-02-19 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Marcos Agramont
CEO | Chief Executive Officer | - | 24-05-17 |
Director/Board Member | - | 30-08-18 | |
Director/Board Member | - | 21-11-18 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+41,50% | 6,2 mld. | |
-22,89% | 4,1 mld. | |
+9,36% | 3,41 mld. | |
-19,39% | 2,83 mld. | |
-11,05% | 2,29 mld. | |
+45,24% | 1,93 mld. | |
+46,81% | 1,51 mld. | |
-7,51% | 1,52 mld. | |
-18,04% | 1,49 mld. |